drugset / Trial / NCT02375217

"Low Dose Sugammadex Combined With Neostigmine and Glycopyrrolate Versus Full Dose Sugammadex for Reversal of Rocuronium-induced Neuromuscular Blockade: a Cost Saving Strategy"

NCT02375217

Phase 4 Completed 56 enrolled American University of Beirut Medical Center
RandomizedParallel-groupTriple-blindTreatment

Summary

Prospective Randomized non inferiority Trial involving adult patients undergoing elective surgery under general anesthesia.56 Patients will be enrolled in 2 groups : full dose sugammadex vs half dose sugammadex for reversal of NMB.

Timeline

Start
2014-10
Primary completion
2015-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Neostigmine Other / unclassified 50 ug/kg Intravenous
Comparator Sugammadex Other / unclassified 1 mg/kg Intravenous
Comparator Sugammadex Other / unclassified 2 mg/kg Intravenous
Comparator Sugammadex Other / unclassified 4 mg/kg Intravenous
Comparator Glycopyrrolate Small molecule 10 ug/kg

Indications

No indication recorded.